Loading
A phase 3 trial of Saruparib, Camizestrant, Abemaciclib, Ribociclib, Palbociclib and Fulvestrant in HR-positive / HER2-negative breast cancer, run by AstraZeneca, now recruiting.
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer is a phase 3 interventional study registered as NCT06380751 by AstraZeneca, with 788 participants planned, started 2024-08-01 and due to reach its primary completion in 2029-12-18. Interventions recorded: Saruparib (AZD5305), Camizestrant, Abemaciclib, Ribociclib, Palbociclib and Fulvestrant.
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant and the tag pipeline.
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant and the tag pipeline.
Shares Camizestrant, Palbociclib, Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca and the tag pipeline.
Shares Camizestrant, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca and the tag pipeline.
Shares Camizestrant, Ribociclib, Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant and the tag pipeline.
Shares Ribociclib, Abemaciclib, Palbociclib, HR-positive / HER2-negative breast cancer and the tag pipeline.